Efficacy and Safety of memanTine in the Treatment Of Frequently symPtomatic Atrial Premature Beats

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.

Also called NCT06501638

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 256 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06501638
Other papers using this trial's data
  • Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial Circulation, 2026-04-21 DOI, PubMed 41853846, PMC13105507 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06501638. Randomized; quadruple masking; primary purpose treatment. Start 2024-08-29 (actual); primary completion 2025-03-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of memanTine in the Treatment Of Frequently symPtomatic Atrial Premature Beats
Acronym
STOP-AP
Condition
Atrial Premature Beats, Contractions, or Systoles
Intervention (Drug)
Memantine Hydrochloride 10 MG
Intervention (Drug)
Placebo
Lead sponsor
Shanghai East Hospital (class: other)

Record details

Record id
cardio:ct-nct06501638
Content hash
c60c533c43454753af75e41a59a1cefa7dcb28e49c83b7c3df2a3f3f72ba2f86